$NBIO - Under the terms of the agreement, Manhattan Bio will perform PTB conjugations to industry standard linker-payloads and will evaluate the resulting ADCs in the in vitro cell assays. The most promising candidates will be prioritized for further development for the treatment of vimentin-positive and potential secondary targets in advanced or metastatic tumors.
https://finance.yahoo.com/news/nascent-biotec...00090.html
https://finance.yahoo.com/news/nascent-biotec...00090.html